H1N1 Countermeasure Development
Award Notice Posted
- Solicitation number
- Not on record
- Agency
-
Defense Threat Reduction Agency
Department of Defense
- Awarded
- to Sarepta Therapeutics, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HDTRA1-10-C-0079 Federal contract award
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- Not on record
- Place of performance
- 4575 SW Research Way, Suite 200 Corvallis, Oregon 97333, United States
Notice details come from SAM.gov. Updated .
Notice text
Added: Aug 06, 2010 8:46 am This Justification and Approval (J&A) document supports an award made under urgent and compelling conditions to AVI BioPharma, Inc. (AVI) for the development of a therapeutic to target the H1N1 influenza virus. The objective of the contract is to accomplish preclinical and Phase 1 clinical development of a lead candidate therapeutic previously designed based on AVI's proprietary technology. The end goal is to have a therapeutic approved by the Food and Drug Administration (FDA) for use under an Emergency Use Authorization (EUA), should an EUA be declared by the FDA with respect to the H1N1 influenza virus.
Files
| File | Type | Posted |
|---|---|---|
| J A_AVI 10-C-0079_signed_REDACTED.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity